Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes. Janumet XR is indicated as an adjunct to diet and ...
Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...
The new formulation, meant to be used as an adjunct to diet and exercise to improve glycemic control, combines sitagliptin (the active component of Januvia [Merck]), with extended-release metformin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback